Musculoskeletal Pain in Patients With Covid-19 Who Have Hospital Care

• Conditions: Covid19

• Registration Number: NCT04632355
• Lead Sponsor: Fondazione Don Carlo Gnocchi Onlus

Brief Summary

Worldwide, the COVID-19 pandemic continues to grow. Although COVID-19 mainly affects the lungs and internal organs, musculoskeletal injury from this disease was reported with the presentation of marked elevation in creatine kinase and lactate dehydrogenase levels. Patients with post-acute COVID-19 are considered patients with a post-intensive syndrome (PICS) that results in loss of functional independence.

In the physical and rehabilitation medical field, various modalities with therapeutic exercise can be used to manage pain by a physical therapist and psychiatrist.

Pain management is particularly important during the COVID-19 pandemic because of the reduced accessibility to hospitals and medical resources.

Detailed Description

The COVID-19 survivors with pain symptoms will participated. In this phase, a face-to-face interview will be conducted to collecting all outcomes about pain.

Study Timeline

• Status Verified: 2020-11
• Study First Submitted: 2020-11-13
• Study First Submitted QC: 2020-11-16
• Study First Posted: 2020-11-17
• Last Update Submitted: 2020-11-17
• Last Update Posted: 2020-11-19
• Study Start: 2020-12-01
• Primary Completion: 2021-07-31
• Study Completion: 2021-07-31

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

• Recovered from COVID-19 infection.
• COVID-19 survivors after hospitalization.
• Musculoskeletal pain.

Exclusion Criteria

• Participants will be excluded also if they score greater than 6 points on the Beck Depression Inventory (BDI) or more than 30 points in the State Trait Anxiety Inventory (STAI), dementia and not Italian speaking due to the high level of language skills required for questionnaires and quantitative sensory testing.
• Psychiatric or neurological disorders

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Self-reported Version of the Leeds Assessment of Neuropathic Symptoms and Signs	Baseline	the characterization of the pain. Total of 24. \> 11 neuropathic pain.
The Hospital Anxiety and Depression Scale	Baseline	To measure psychological status. 0-7 = Normal; 8-10 = Borderline abnormal (borderline case), 11-21 = Abnormal (case)
EuroQol-5D	Baseline	To measure quality of life, grade ranging from 0 (the worst possible health status) to 100 (the best possible health status)
PainDETEC	Baseline	the characterization of the pain

Trial Locations

Locations (1)

Jorge Hugo Villafañe; 🇮🇹 Milan, Italy